ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2528

Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis

Risa Wakiya1, Kiyo Ueeda 2, Hiromi Shimada 2, Shusaku Nakashima 1, Mai Mahmoud Fahmy Mansour 1, Mikiya Kato 1, Taichi Miyagi 1, Tomohiro Kameda 1 and Hiroaki Dobashi 2, 1Kagawa University, Kagawa, 2Kagawa University, Kagawa, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Hydroxychloroquine, il-8 and MRP8, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Clinical Poster III: Treatment

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ treatment on the expression of pro-inflammatory cytokines, which plays an important role in SLE pathogenesis. The aim of this study is to clarify the effect of additional HCQ treatment on pro-inflammatory cytokines in SLE patients with low disease activity(LDA).

Methods: All patients with LDA enrolled in this study started HCQ treatment and had been receiving oral HCQ continuously for at least 3 months without using other immunosuppressive treatments or glucocorticoids. LDA was defined as SELENA-SLEDAI score of 8 or less with no activity in major organ systems and current prednisolone or equivalent dose of 10mg per day or less and well-tolerated maintenance doses of immunosuppressant. Serum levels of IFN-α, MRP8, MRP14, TNF-α, IL-2, IL-6, IL-8, VEGF-A, MCP-1, MIP-1α, IL-1β, IL-1ra, and G-CSF were measured at the time of HCQ administration and 3 months later using ELISA (CircuLex ELISA Kit, MBL)(Human IFN-alpha ELISA Kit, R&D) or a multiplex immunoassay (Luminex Assay, R&D). Data was analyzed using JMP® 13 software (SAS Institute Inc., Cary, NC, USA).

Results: 42 patients were enrolled in this study (M:F; 4:38, average age; 41.3±13.3; Table 1). 19 cases were in sustained remission of lupus nephritis(LN) patients. Serum levels of MRP8, MRP14 and IL-1ra at baseline were significantly higher in patients with a history of LN compared with those without LN (p=0.012, p=0.0043 and p=0.0092, respectively). Serum levels of MRP8, MRP14, TNF-α, IL-6, VEGF-A, IL-1ra, and IL-2 decreased significantly 3 months after additional HCQ treatment. The expressions of IFN-α didn’t decrease significantly in 9 cases that could be detected.
Serum levels of IL-8 and MIP-1a decreased 3 months after additional HCQ treatment, but the difference was not statistically significant (p=0.211, p=0.109). However, serum levels of IL-8 same as VEGF-A significantly decreased in patients with a history of LN (with LN: IL-8, p=0.0026; VEGF-A, p=0.048; without LN: IL-8, p=0.370; VEGF-A, p=0.284). In addition, the magnitude of the changes in serum IL-8 levels in patients with a history of LN was significantly higher than in those without a history of LN (p=0.0039; Figure 1). The changes of IL-8 levels were correlated with those of serum MRP8 (r=0.32, p=0.049, Figure2).

Conclusion: Additional HCQ treatment could decrease the several pro-inflammatory cytokines expression in SLE patients with LDA, especially in LN. Additionally, our data indicates that the effect of additional HCQ treatment could reduce the IL-8 expression in remission LN subjects significantly, which is reported to be associated with improvement of LN prognosis. HCQ use should be considered to be prescribed for all SLE patients as described in EULAR recommendation 2019.

Table 1. Characteristics of SLE patients enrolled in this study
*1 Two patients received multiple immunosuppressants.
*2 Four patients received antiplatelet agent and anticoagulant agent.
*3 Anti-dsDNA positive means anti ds-DNA titer increases over 12 IU/ml.
*4 Low complement means any of C3, C4 and CH50 decreases to less 68mg/dl, less 12mg/dl, less 30U/ml.

Figure 1.The magnitude of changes in serum IL-8 levels in patients with a history of LN were significantly higher than in patients without a history of LN. For statistical analyses * p<0.05, NS: Not significant, P value: Steel-Dwass test

Figure 2. Correlation between the changes of IL-8 and those of MRP8 -r=0.32 p<0.05-.


Disclosure: R. Wakiya, None; K. Ueeda, None; H. Shimada, None; S. Nakashima, None; M. Mahmoud Fahmy Mansour, None; M. Kato, None; T. Miyagi, None; T. Kameda, None; H. Dobashi, None.

To cite this abstract in AMA style:

Wakiya R, Ueeda K, Shimada H, Nakashima S, Mahmoud Fahmy Mansour M, Kato M, Miyagi T, Kameda T, Dobashi H. Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-additional-administration-of-hcq-on-pro-inflammatory-cytokine-expression-especially-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-additional-administration-of-hcq-on-pro-inflammatory-cytokine-expression-especially-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology